177 related articles for article (PubMed ID: 11821940)
1. Long-term RNase P-mediated inhibition of HIV-1 replication and pathogenesis.
Hnatyszyn H; Spruill G; Young A; Seivright R; Kraus G
Gene Ther; 2001 Dec; 8(24):1863-71. PubMed ID: 11821940
[TBL] [Abstract][Full Text] [Related]
2. Cross-clade inhibition of HIV-1 replication and cytopathology by using RNase P-associated external guide sequences.
Kraus G; Geffin R; Spruill G; Young AK; Seivright R; Cardona D; Burzawa J; Hnatyszyn HJ
Proc Natl Acad Sci U S A; 2002 Mar; 99(6):3406-11. PubMed ID: 11904403
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of HIV-1 replication by retroviral vectors expressing monomeric and multimeric hammerhead ribozymes.
Ramezani A; Ding SF; Joshi S
Gene Ther; 1997 Aug; 4(8):861-7. PubMed ID: 9338016
[TBL] [Abstract][Full Text] [Related]
4. Suppression of HIV-1 replication by a combination of endonucleolytic ribozymes (RNase P and tRNnase ZL).
Ikeda M; Habu Y; Miyano-Kurosaki N; Takaku H
Nucleosides Nucleotides Nucleic Acids; 2006; 25(4-6):427-37. PubMed ID: 16838836
[TBL] [Abstract][Full Text] [Related]
5. Lentiviral siRNAs targeting multiple highly conserved RNA sequences of human immunodeficiency virus type 1.
Chang LJ; Liu X; He J
Gene Ther; 2005 Jul; 12(14):1133-44. PubMed ID: 15750613
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of simian/human immunodeficiency virus replication in CD4+ T cells derived from lentiviral-transduced CD34+ hematopoietic cells.
Braun SE; Wong FE; Connole M; Qiu G; Lee L; Gillis J; Lu X; Humeau L; Slepushkin V; Binder GK; Dropulic B; Johnson RP
Mol Ther; 2005 Dec; 12(6):1157-67. PubMed ID: 16168713
[TBL] [Abstract][Full Text] [Related]
7. High transdominant RevM10 protein levels are required to inhibit HIV-1 replication in cell lines and primary T cells: implication for gene therapy of AIDS.
Plavec I; Agarwal M; Ho KE; Pineda M; Auten J; Baker J; Matsuzaki H; Escaich S; Bonyhadi M; Böhnlein E
Gene Ther; 1997 Feb; 4(2):128-39. PubMed ID: 9081703
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of HIV-1 replication by novel lentiviral vectors expressing transdominant Rev and HIV-1 env antisense.
Mautino MR; Morgan RA
Gene Ther; 2002 Apr; 9(7):421-31. PubMed ID: 11938457
[TBL] [Abstract][Full Text] [Related]
9. Long-term survival and concomitant gene expression of ribozyme-transduced CD4+ T-lymphocytes in HIV-infected patients.
Macpherson JL; Boyd MP; Arndt AJ; Todd AV; Fanning GC; Ely JA; Elliott F; Knop A; Raponi M; Murray J; Gerlach W; Sun LQ; Penny R; Symonds GP; Carr A; Cooper DA
J Gene Med; 2005 May; 7(5):552-64. PubMed ID: 15655805
[TBL] [Abstract][Full Text] [Related]
10. Retrovirally expressed anti-HIV ribozymes confer a selective survival advantage on CD4+ T cells in vitro.
Klebba C; Ottmann OG; Scherr M; Pape M; Engels JW; Grez M; Hoelzer D; Klein SA
Gene Ther; 2000 Mar; 7(5):408-16. PubMed ID: 10694823
[TBL] [Abstract][Full Text] [Related]
11. Lentiviral transduction of human T-lymphocytes with a RANTES intrakine inhibits human immunodeficiency virus type 1 infection.
Schroers R; Davis CM; Wagner HJ; Chen SY
Gene Ther; 2002 Jul; 9(13):889-97. PubMed ID: 12080383
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of HIV-1 replication by combined expression of gag dominant negative mutant and a human ribonuclease in a tightly controlled HIV-1 inducible vector.
Cara A; Rybak SM; Newton DL; Crowley R; Rottschafer SE; Reitz MS; Gusella GL
Gene Ther; 1998 Jan; 5(1):65-75. PubMed ID: 9536266
[TBL] [Abstract][Full Text] [Related]
13. Increased rate of HIV-1 entry and its cytopathic effect in CD4+/CXCR4+ T cells expressing relatively high levels of CD26.
Callebaut C; Jacotot E; Blanco J; Krust B; Hovanessian AG
Exp Cell Res; 1998 Jun; 241(2):352-62. PubMed ID: 9637777
[TBL] [Abstract][Full Text] [Related]
14. Ex vivo transduction and expansion of CD4+ lymphocytes from HIV + donors: prelude to a ribozyme gene therapy trial.
Leavitt MC; Yu M; Wong-Staal F; Looney DJ
Gene Ther; 1996 Jul; 3(7):599-606. PubMed ID: 8818647
[TBL] [Abstract][Full Text] [Related]
15. Activity and cleavage site specificity of an anti-HIV-1 hairpin ribozyme in human T cells.
Yamada O; Kraus G; Leavitt MC; Yu M; Wong-Staal F
Virology; 1994 Nov; 205(1):121-6. PubMed ID: 7975207
[TBL] [Abstract][Full Text] [Related]
16. Expression of mutant and wild-type gag proteins for gene therapy in HIV-1 infection.
Miele G; Lever AM
Gene Ther; 1996 Apr; 3(4):357-61. PubMed ID: 8732168
[TBL] [Abstract][Full Text] [Related]
17. Anti-HIV genetic treatment of antigen-specific human CD4 lymphocytes for adoptive immunotherapy of opportunistic infections in AIDS.
Manca F; Fenoglio D; Franchin E; Saverino D; Li Pira G; Buffa F; Bignardi D; Del Pup L; Palù G
Gene Ther; 1997 Nov; 4(11):1216-24. PubMed ID: 9425445
[TBL] [Abstract][Full Text] [Related]
18. Silencing of HIV-1 with RNA interference: a multiple shRNA approach.
ter Brake O; Konstantinova P; Ceylan M; Berkhout B
Mol Ther; 2006 Dec; 14(6):883-92. PubMed ID: 16959541
[TBL] [Abstract][Full Text] [Related]
19. Effective inhibition of HIV-1 replication in cultured cells by external guide sequences and ribonuclease.
Endo Y; Miyano-Kurosaki N; Kitano M; Habu Y; Takaku H
Nucleic Acids Res Suppl; 2001; (1):213-4. PubMed ID: 12836340
[TBL] [Abstract][Full Text] [Related]
20. Modulation of specific surface receptors and activation sensitization in primary resting CD4+ T lymphocytes by the Nef protein of HIV-1.
Keppler OT; Tibroni N; Venzke S; Rauch S; Fackler OT
J Leukoc Biol; 2006 Mar; 79(3):616-27. PubMed ID: 16365153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
